EDB Announces General Availability of BigAnimal, PostgreSQL Database in the Cloud
2.11.2021 15:00:00 EET | Business Wire | Press release
EDB, a leading contributor to PostgreSQL®, today announced the general availability of its BigAnimal™ offering, the first fully-managed PostgreSQL database in the cloud with compatibility for Oracle database technology. Built and backed by the world’s largest roster of PostgreSQL engineers, BigAnimal is for enterprises looking to deploy their most demanding databases into the cloud.
“BigAnimal was built in direct response to what our customers told us was missing from existing cloud Postgres offerings,” said EDB president and CEO, Ed Boyajian. “These improvements aren’t incremental - they’re transformational. We’ve made no compromises. This means you get fanatical attention from the biggest team in Postgres, native compatibility with Oracle database technology, and extreme high availability. And we run it all inside your cloud account.”
Accelerate Business with the Best Cloud PostgreSQL
Customers who are building serious cloud applications are realizing that they can’t get what they need from the basic PostgreSQL offerings available today. Without the transparency, control, and performance tuning required for their most demanding workloads, they are held back from moving fully into the cloud. BigAnimal responds to these needs by giving organizations granular control over the database within their own accounts and all the enterprise PostgreSQL capabilities EDB has been developing over the past 15 years - while being fully managed by EDB.
Specifically, with BigAnimal, enterprises will experience the following benefits:
- Partner with PostgreSQL builders. For over a decade, PostgreSQL users have counted on EDB for their on-premises deployments. Now with BigAnimal, users can also rely on unequaled support from EDB’s world-class PostgreSQL experts.
- Migrate applications on Oracle databases to PostgreSQL on Azure with little to no changes needed. With BigAnimal, customers can reduce costs, time, and risks when migrating workloads from legacy Oracle databases to cloud environments. BigAnimal’s deep compatibility with Oracle database technology and comprehensive migration tools address a critical need for enterprises who want to move quickly without leaving behind all their legacy database investments in code, skill sets, and resources.
- Increase transparency and control of their cloud PostgreSQL. BigAnimal runs in a customer’s cloud account, allowing them to closely manage, secure, and optimize their PostgreSQL along with their other infrastructure according to their business needs and spend commitments. BigAnimal also gives users an unprecedented level of control over their PostgreSQL with superuser access to precisely tweak database internals.
- Minimize complexity with the same PostgreSQL everywhere. EDB Postgres users can expect a uniform database experience, from EDB Postgres on premises to BigAnimal on Azure. This includes the ability to use their existing PostgreSQL skill sets, incorporate the database into their DevOps pipelines, and leverage EDB Postgres Advanced enterprise capabilities, such as enhanced security, performance management, and compatibility with Oracle database technology. With support for license portability, EDB also allows customers to easily deploy PostgreSQL whenever, wherever their business requires.
According to Carl Olofson, research vice president, Data Management Software, IDC: “In 2021, we saw a significant rise in cloud infrastructure spend and expect it to soon surpass non-cloud infrastructure. With this growing reliance on cloud platforms, many companies don’t have the in-house skills to deploy, manage, and optimize their databases. Considering EDB’s long track record of building and supporting Postgres, companies have a strong option for transitioning smoothly and optimizing their cloud database operations.”
For more information about EDB and BigAnimal and to sign up for a trial, please visit www.biganimal.com.
EnterpriseDB, EDB and Postgres Enterprise Manager are registered trademarks of EnterpriseDB Corporation. EDB Postgres and BigAnimal are trademarks of EnterpriseDB Corporation.
Postgres, PostgreSQL, and the Slonik Logo are trademarks or registered trademarks of the PostgreSQL Community Association of Canada, and used with their permission.
About EDB
PostgreSQL is increasingly the database of choice for organizations looking to boost innovation and accelerate business. EDB’s enterprise-class software extends PostgreSQL, helping our customers get the most out of it both on premises and in the cloud. And our 24x7 global support, professional services, and training help our customers control risk, manage costs, and scale efficiently. With 16 offices worldwide, EDB serves over 5,000 customers, including leading financial services, government, media and communications, and information technology organizations. To learn about PostgreSQL for people, teams, and enterprises, visit EDBpostgres.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005218/en/
Contact information
Kate Connors
PAN Communications
781-820-3767
enterprisedb@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
